Immunogenicity and influence on disease activity of recombinant zoster vaccine in patients with rheumatoid arthritis treated with disease-modifying antirheumatic drugs (DMARDs)
Authors' conclusion
RZV is robustly immunogenic and has a clinically acceptable safety profile in elderly patients with RA receiving DMARDs.
Study context
- Population
- Patients with rheumatoid arthritis (RA) aged ≥50 years treated with DMARDs, receiving two intramuscular RZV doses 2 months apart53 RA patients and 10 controls
- Participants
- 20 / 23 / 10 / 10
- Exposure
- RZV in RA patients treated with csDMARDs vs bDMARDs vs tsDMARDs, plus control individuals
- csDMARDsn = 20
- b-DMARDsn = 23
- ts-DMARDsn = 10
- Controln = 10reference
- Outcome
- Varicella-zoster virus (VZV)-specific CD4+ T cell responses (CMI) and IgG antibody responses (HI)
- Follow-up
- 3 months after first RZV
Main finding
As reported in the abstract
VZV-specific CMI and HI after RZV vs prevaccination · 3 months
- CMI and HI significantly increased in all three DMARD-treated RA groups vs prevaccination
- p<0.001-0.014
Observational data: associations, not effects.
Further findings
Disease activity (DAS28-CRP, CDAI) · 6 months after first vaccination
- No significant increases in disease activity indices
Safety
RZV-induced RA flares · 6 months
- Flares in two patients, mild and controllable
- 3.8%
Adverse events · 6 months
- No significant increases in adverse events
Original publication
Immunogenicity and influence on disease activity of recombinant zoster vaccine in patients with rheumatoid arthritis treated with DMARDs. RMD Open. Published 21 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →